Cullinan Oncolog Rg
Cullinan Therapeutics, Inc., a clinical‑stage biopharma focused on cancer and autoimmune disease, leads zipalertinib (Phase 3 NSCLC) and CLN‑978 (T‑cell engager for SLE/RA), with Phase 1 assets CLN‑619, CLN‑049, CLN‑617, and partnerships with Adimab and Taiho.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 111
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.